Stahl S
Department of Psychiatry, University of California, San Diego 92122.
Psychopharmacol Bull. 1994;30(1):39-43.
Numerous observations support the notion that serotonin (5-hydroxytryptamine; 5-HT) and its multiple receptor subtypes are linked not only to the biological basis of depression, but also to the mechanism of action of antidepressant drugs. A general hypothesis of 5-HT receptor dysregulation in depression suggests that 5-HT1A receptors may be down-regulated, whereas 5-HT2 receptors may be up-regulated and display an inadequate ability to convert receptor occupancy by 5-HT into an adequate physiological response. Preclinical studies show that numerous antidepressants down-regulate both 5-HT1A and 5-HT2 receptors. Clinical studies using post mortem tissues, neuroendocrine probes, and platelet models also confirm that antidepressants down-regulate 5-HT receptors in depressed patients. In some cases this down-regulation correlates with measures of clinical antidepressant responsiveness. This correlation supports the hypothesis that down-regulation of 5-HT receptors, particularly the 1A and 2 subtypes, may be linked to the mechanism of action of numerous antidepressant drugs.
大量观察结果支持这样一种观点,即血清素(5-羟色胺;5-HT)及其多种受体亚型不仅与抑郁症的生物学基础有关,还与抗抑郁药物的作用机制有关。抑郁症中5-HT受体失调的一个普遍假说是,5-HT1A受体可能下调,而5-HT2受体可能上调,并且将5-HT对受体的占据转化为充分生理反应的能力不足。临床前研究表明,许多抗抑郁药会下调5-HT1A和5-HT2受体。使用尸检组织、神经内分泌探针和血小板模型的临床研究也证实,抗抑郁药会下调抑郁症患者的5-HT受体。在某些情况下,这种下调与临床抗抑郁反应性的测量结果相关。这种相关性支持了这样一种假说,即5-HT受体,特别是1A和2亚型的下调,可能与许多抗抑郁药物的作用机制有关。